Author

T. R. Aunins

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:bacteria (other)· 1 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1 Organism:E. coli· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Chatterjee· 3 shared C. M. Courtney· 2 shared C. R. McCollum· 1 shared J. K. Campos· 1 shared J. M. Brown· 1 shared K. A. Eller· 1 shared K. E. Erickson· 1 shared K. Erickson· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

A. Chatterjee

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Safety and biodistribution of NanoligomersTM targeting SARS-CoV-2 genome for treatment of COVID-19

C. R. McCollum, C. M. Courtney, N. J. O'Connor, T. R. Aunins, T. X. Jordan, K. Rogers, S. Brindley, J. M. Brown, P. Nagpal, A. Chatterjee

This paper evaluates the safety and biodistribution of a novel Nanoligomer targeting SARS-CoV-2 in mice, showing it is safe, nontoxic, and effectively distributed throughout the body.

bioRxiv · Jul 19, 2022Bioengineering

Transcriptome-based design of antisense inhibitors re-sensitizes CRE E. coli to carbapenems

T. R. Aunins, K. Erickson, A. Chatterjee

This study uses transcriptomics to identify gene targets for antisense inhibitors that re-sensitize CRE E. coli to carbapenems.

bioRxiv · Dec 16, 2019 · PreprintMicrobiology

Facile Accelerated Specific Therapeutic (FAST) Platform to Counter Multidrug-Resistance Bacteria

K. A. Eller, T. R. Aunins, C. M. Courtney, J. K. Campos, P. B. Otoupal, K. E. Erickson, N. E. Madinger, A. Chatterjee

The paper introduces a FAST platform that rapidly develops therapies against multidrug-resistant bacteria using sequence-specific PNAs and a novel delivery system.

bioRxiv · Nov 21, 2019 · PreprintBioengineering